We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Idex (IEX) Up 0.1% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Idex (IEX - Free Report) . Shares have added about 0.1% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Idex due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for IDEX Corporation before we dive into how investors and analysts have reacted as of late.
IDEX Beats Q2 Earnings Estimates on HST Momentum, Raises View
IDEX delivered second-quarter 2026 adjusted earnings of $2.32 per share, topping the Zacks Consensus Estimate of $2.10. Adjusted earnings rose 12.1% year over year. Net sales of $920.6 million beat the consensus mark of $902.43 million by 2% and increased 6.4% from the year-ago quarter. Organic sales increased 5% year over year. Acquisitions had a positive impact of 1% on sales, while foreign currency translation had no impact.
Results were driven by solid traction in the Health & Science Technologies segment, where higher volumes in AI-linked data center power and semiconductor end markets, along with strength in space and defense, supported growth. IDEX also posted record orders of more than $1 billion, signaling improving demand.
Segmental Details
Net sales from the Fluid & Metering Technologies segment totaled $317.1 million, up 2% year over year. The Zacks Consensus Estimate was pegged at $314 million. Organic sales increased 1% year over year. Foreign currency translation had a positive impact of 1% on sales.
Net sales from the Health & Science Technologies segment totaled $415 million, up 14% year over year. The consensus estimate was pegged at $407 million. Organic sales increased 12% year over year. Acquisitions/divestitures had a positive impact of 2% on sales, while foreign currency translation had no impact.
Net sales from the Fire & Safety/Diversified Products segment totaled $189.9 million, which decreased 1% year over year. The Zacks Consensus Estimate was pegged at $189 million. Organic sales decreased 1% on a year-over-year basis, while acquisitions/divestitures and foreign currency translation had no impact on sales.
Margin Profile
IDEX’s cost of sales increased 4.4% year over year to $493.8 million. The adjusted gross margin was 46.4%, up 110 basis points year over year, reflecting net productivity improvements, volume leverage and positive price-cost dynamics, partially offset by unfavorable mix. Selling, general and administrative expenses increased 10.1% year over year to $224.1 million.
Adjusted EBITDA rose 8.9% to $258.3 million and the adjusted EBITDA margin improved 70 basis points to 28.1%. Operating income increased 6.4% to $199.9 million, aided by improved operating performance. The operating margin was 21.7%, unchanged year over year on a rounded basis. Interest expense (net) decreased to $15.1 million from $15.6 million in the prior-year period.
Balance Sheet and Cash Flow of IDEX
At the end of the second quarter, IDEX’s cash and cash equivalents were $621.3 million compared with $580 million at the end of 2025. Long-term borrowings (net) were $1.86 billion compared with $1.82 billion at the end of 2025.
In the first six months of 2026, IDEX generated net cash of $303.7 million from operating activities, up 13.6% from the year-ago period. Capital expenditures were $40.7 million compared with $29.1 million in the prior-year period. In the same period, free cash flow was $263 million, up 10.4% year over year.
IDEX paid out dividends totaling $106.7 million in the first six months of 2026, up 0.8% year over year.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
At this time, Idex has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Following the exact same course, the stock was allocated a score of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Idex has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Idex (IEX) Up 0.1% Since Last Earnings Report?
A month has gone by since the last earnings report for Idex (IEX - Free Report) . Shares have added about 0.1% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Idex due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for IDEX Corporation before we dive into how investors and analysts have reacted as of late.
IDEX Beats Q2 Earnings Estimates on HST Momentum, Raises View
IDEX delivered second-quarter 2026 adjusted earnings of $2.32 per share, topping the Zacks Consensus Estimate of $2.10. Adjusted earnings rose 12.1% year over year. Net sales of $920.6 million beat the consensus mark of $902.43 million by 2% and increased 6.4% from the year-ago quarter. Organic sales increased 5% year over year. Acquisitions had a positive impact of 1% on sales, while foreign currency translation had no impact.
Results were driven by solid traction in the Health & Science Technologies segment, where higher volumes in AI-linked data center power and semiconductor end markets, along with strength in space and defense, supported growth. IDEX also posted record orders of more than $1 billion, signaling improving demand.
Segmental Details
Net sales from the Fluid & Metering Technologies segment totaled $317.1 million, up 2% year over year. The Zacks Consensus Estimate was pegged at $314 million. Organic sales increased 1% year over year. Foreign currency translation had a positive impact of 1% on sales.
Net sales from the Health & Science Technologies segment totaled $415 million, up 14% year over year. The consensus estimate was pegged at $407 million. Organic sales increased 12% year over year. Acquisitions/divestitures had a positive impact of 2% on sales, while foreign currency translation had no impact.
Net sales from the Fire & Safety/Diversified Products segment totaled $189.9 million, which decreased 1% year over year. The Zacks Consensus Estimate was pegged at $189 million. Organic sales decreased 1% on a year-over-year basis, while acquisitions/divestitures and foreign currency translation had no impact on sales.
Margin Profile
IDEX’s cost of sales increased 4.4% year over year to $493.8 million. The adjusted gross margin was 46.4%, up 110 basis points year over year, reflecting net productivity improvements, volume leverage and positive price-cost dynamics, partially offset by unfavorable mix. Selling, general and administrative expenses increased 10.1% year over year to $224.1 million.
Adjusted EBITDA rose 8.9% to $258.3 million and the adjusted EBITDA margin improved 70 basis points to 28.1%. Operating income increased 6.4% to $199.9 million, aided by improved operating performance. The operating margin was 21.7%, unchanged year over year on a rounded basis. Interest expense (net) decreased to $15.1 million from $15.6 million in the prior-year period.
Balance Sheet and Cash Flow of IDEX
At the end of the second quarter, IDEX’s cash and cash equivalents were $621.3 million compared with $580 million at the end of 2025. Long-term borrowings (net) were $1.86 billion compared with $1.82 billion at the end of 2025.
In the first six months of 2026, IDEX generated net cash of $303.7 million from operating activities, up 13.6% from the year-ago period. Capital expenditures were $40.7 million compared with $29.1 million in the prior-year period. In the same period, free cash flow was $263 million, up 10.4% year over year.
IDEX paid out dividends totaling $106.7 million in the first six months of 2026, up 0.8% year over year.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
At this time, Idex has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Following the exact same course, the stock was allocated a score of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Idex has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.